Form 4: Aadi Bioscience Director Anupam Dalal Reports Significant Share Acquisition

Director Anupam Dalal reports acquiring 1,561,000 shares of Aadi Bioscience, Inc. common stock at $2.4 per share on March 4, 2025.

Summary

• On March 4, 2025, Anupam Dalal, a director of Aadi Bioscience, Inc., reported acquiring 1,561,000 shares of common stock at a price of $2.4 per share.
• Following this transaction, Dalal directly owns 1,130 shares and indirectly owns 3,410,402 shares.
• The indirect ownership includes shares held by Acuta Capital Fund, LP (2,535,488 shares) and Acuta Opportunity Fund, LP (874,914 shares).
• Acuta Capital Partners, LLC, where Dalal serves as Chief Investment Officer and Managing Member, is the general partner of both Acuta Capital and Acuta Opportunity Fund.
• Dalal disclaims beneficial ownership of the shares held by Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's significant share purchase, which suggests confidence in the company's future. However, it's important to consider the context and reasons behind the purchase.

Positives

• A director's significant investment in the company may signal confidence in its future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The increased demand for shares could potentially lead to a slight increase in the stock price.

Key Dates